Huntington National Bank Boosts Position in ICU Medical, Inc. (NASDAQ:ICUI)

Huntington National Bank boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,402 shares of the medical instruments supplier’s stock after purchasing an additional 82 shares during the period. Huntington National Bank’s holdings in ICU Medical were worth $218,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Franklin Resources Inc. grew its position in ICU Medical by 65.1% during the fourth quarter. Franklin Resources Inc. now owns 19,333 shares of the medical instruments supplier’s stock valued at $3,000,000 after buying an additional 7,625 shares during the period. Alliancebernstein L.P. boosted its stake in shares of ICU Medical by 0.5% during the 4th quarter. Alliancebernstein L.P. now owns 26,107 shares of the medical instruments supplier’s stock worth $4,051,000 after acquiring an additional 136 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of ICU Medical during the 4th quarter valued at $249,000. Pictet Asset Management Holding SA increased its stake in shares of ICU Medical by 11.8% in the 4th quarter. Pictet Asset Management Holding SA now owns 3,287 shares of the medical instruments supplier’s stock worth $510,000 after purchasing an additional 346 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new position in ICU Medical in the 4th quarter worth $578,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Down 1.6 %

Shares of ICUI opened at $139.32 on Friday. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $3.42 billion, a PE ratio of -30.49 and a beta of 0.73. The business’s 50 day moving average is $151.64 and its 200 day moving average is $162.55.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ICUI. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday. Raymond James set a $97.00 price target on shares of ICU Medical in a report on Wednesday, March 12th. Finally, Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $168.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.